Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)
Clinical trial NCT01317875 · COMPLETED
Trial details
- NCT number
- NCT01317875
- Sponsor
- Incyte Corporation
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2011-03-31
- Primary completion
- 2019-12-31
- Enrollment
- 69
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.